Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I study of MK2206 (an AKT inhibitor)and gefitinib in nonsmall cell lung
cancer patients who failed prior chemotherapy and epidermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI). The patient population is enriched for EGFR mutations.
The purpose of this study is to determine whether it is safe to administered MK-2206 in
combination with gefitinib in adult patients with locally advanced or metastatic non-small
cell lung cancer. The second purpose of this study is to define the MTD (Maximum Tolerated
Dose) of MK-2206 when combined with gefitinib.
A standard 3-3 dose escalation scheme of MK-2206 with fix dose gefitinib is used in this
study.